Compare Charles River Laboratories Intl. Inc (CRL) vs FTAI Aviation Ltd (FTAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs FTAI Aviation Ltd — how do they compare? Charles River Laboratories Intl. Inc trades at $231.94 (market cap $11.14B), while FTAI Aviation Ltd trades at $208.19 (market cap $21.17B). The key difference: FTAI Aviation Ltd is the larger of the two by market cap, and FTAI Aviation Ltd pays a 0.73% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | FTAI | |
|---|---|---|
Market Cap | $11.14B | $21.17B |
Sector | Health | Industrials |
52-Week High | $233.60 | $310.04 |
52-Week Low | $145.57 | $109.92 |
Enterprise Value | $14.00B | $24.21B |
Dividend Yield | — | 0.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
FTAI Aviation trades at $209.88, down 7.68% today, amid a bearish technical signal. The stock has missed earnings estimates for three consecutive quarters, though revenue and net income remain robust. Recent news highlights strategic collaborations and growth in data center power solutions. Analyst consensus is unanimously bullish with 18 buy ratings.
The outlook is supported by strong fundamentals and growth initiatives, but risks include earnings misses and high valuation multiples. The stock's near-term performance hinges on Q2 2026 results and execution of new business segments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →
